News

Pfizer COVID drug Paxlovid is effective with high-risk people: updates

An experimental antiviral drug from Pfizer to help combat COVID-19, delivered in a five-day course of pills, reduced hospitalization or death among high-risk people by 89%, according to a final analysis of a previously released study.

A second study of people at average risk found the drug reduced their chances of developing severe disease by 70%, compared to a placebo. To get these results, the drug, called Paxlovid, must be given within three days of the beginning of COVID-19 symptoms — which will require people to quickly test and request a prescription once they feel ill.

The drug was tested on people who were not vaccinated but is also expected to protect people who have so-called breakthrough infections after vaccination.

Paxlovid appeared safe in both studies, which included nearly 3,500 volunteers, half of whom received a placebo. Lab studies also suggest the antiviral will remain potent against the omicron variant, which has been rapidly spreading across the globe.


Source link

Show More

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button